Histopathological findings for prediction of liver cirrhosis and survival in biliary atresia patients after Kasai procedure

Gunadi1*, Dian Nirmala Sirait1, Leila Rakhma Budianti1, Vincentia Meta Widya Paramita1, Aditya Rifqi Fauzi1, Fiko Ryantono1, Dwiki Afandy1, Naomi Yoshuanta2, Hanggoro Tri Rinonce2 and Akhmad Makhmudi1

Abstract

Background: Without early recognition and Kasai procedure, biliary atresia (BA) results in liver cirrhosis and leads to either transplantation or death at a young age. We aimed to characterize the liver histopathological findings for prediction of cirrhosis and survival in BA patients after Kasai surgery.

Methods: We retrospectively reviewed all histopathological results for BA patients who underwent liver biopsy during Kasai surgery from August 2012 to December 2018 in Dr. Sardjito Hospital, Yogyakarta, Indonesia.

Results: Fifty infants with BA were ascertained in our study, of whom 27 were males and 23 were females. The median age of Kasai procedure was 102.5 days (interquartile range (IQR), 75.75–142.25 days). There were 33 (66%) and 17 (34%) BA patients with and without liver cirrhosis, respectively, while the overall survival was 52%. The patients with a severe bile duct proliferation, severe cholestasis, and severe portal inflammation have a higher risk by 27-, 22-, and 19.3-fold, respectively, to develop liver cirrhosis compared with patients with a moderate/mild bile duct proliferation, moderate/mild/without cholestasis, and moderate/mild portal inflammation, respectively ($p = 3.6 \times 10^{-6}, 5.6 \times 10^{-4}$, and $1.6 \times 10^{-3}$, respectively), while the giant cell transformation was not associated with the development of liver cirrhosis ($p = 0.77$). The bile duct proliferation was strongly correlated with cholestasis and portal inflammation ($p = 7.3 \times 10^{-5}$ and $2 \times 10^{-3}$, respectively), while the giant cell transformation was also significantly correlated with portal inflammation ($p = 0.016$). Interestingly, the age at Kasai procedure was strongly associated with the development of liver cirrhosis ($p = 0.02$), but not with the patients’ survival ($p = 0.33$), while the degree of fibrosis and cholestasis were significantly correlated with the patients’ survival, with HR of 3.9 (95% CI = 1.7–9.0; $p = 0.017$) and 3.1 (95% CI = 1.4–7.0; $p = 0.016$), respectively.

Conclusions: Histopathological findings of bile duct proliferation, cholestasis, and portal inflammation can predict the liver cirrhosis development in patients with BA. Furthermore, degree of fibrosis and cholestasis affect the patients’ survival following the Kasai operation.

Keywords: Biliary atresia, Histopathological findings, Liver cirrhosis, Kasai procedure, Prognosis, Patient survival

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Biliary atresia (BA) is characterized by a progressive destructive inflammatory cholangiopathy that affects both the intra- and extrahepatic bile ducts [1, 2]. Its incidence varies among different ethnicities [3–5]. The role of histopathological findings on the prognosis of patients with BA following Kasai operation has been reported with conflicting results [6–8]. Furthermore, BA will lead to liver cirrhosis and results in either transplantation or death at a young age if without early diagnosis and Kasai surgery [1, 2]. Therefore, it is necessary to predict the development of liver cirrhosis and survival in BA patients after Kasai surgery. We aimed to characterize the liver histopathological findings for prediction of cirrhosis and survival in patients with BA following Kasai operation.

Methods
Patients
We retrospectively reviewed all histopathological results for patients with BA who underwent liver biopsy during Kasai surgery from August 2012 to December 2018 in our institution, Indonesia.

The study included 55 BA cases, of whom 5 subjects were excluded due to the incomplete data. Fifty patients were included for final analysis (Table 1).

The study got an approval by the Ethical Committee of Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital (KE/FK/528/EC/2015 and KE/FK/0506/EC/2020).

Histopathological analysis
Histopathological examination was performed by two pathologists at Dr. Sardjito Hospital using hematoxylin and eosin staining. Five histopathological findings were analyzed, including fibrosis, bile duct proliferation, cholestasis, portal inflammation and giant cell transformation, according to previous studies [6, 7, 9, 10].

Fibrosis was classified as follows: 1) mild, fibrosis ranging from portal fibrous expansion to bridging fibrosis encompassing <50% of portal tracts; 2) moderate, bridging fibrosis with >50% of portal tracts encompassed without nodular architecture; and 3) severe (cirrhosis), bridging fibrosis with >50% of portal tracts encompassed and nodular architecture (Fig. 1) [6, 10].

The following grading was used for bile duct proliferation: 1) mild, 5–9 bile ducts per portal tract, 2) moderate, ≥10 bile ducts per portal tract, and 3) severe, ≥10 bile ducts per portal tract and the ducts are elongated attenuated and angulated; whereas cholestasis was classified as: 1) absent, 2) mild, accumulation of bile in centrolobular hepatocytes, 3) moderate, accumulation of bile in centrolobular and periportal hepatocytes or even in portal tracts, and 4) severe, presence of bile infarcts (Fig. 1) [6].

Portal inflammation was categorized as: 1) mild, cells are present in <1/3 portal tracts, 2) moderate, cells are present in >1/3–2/3 portal tracts, and 3) severe, dense packing of cells present in >2/3 portal tracts [6]; while giant cell transformation was assigned as positive and negative (Fig. 1) [7, 9].

Statistical analysis
We provided the data as number and median (interquartile range, IQR) and utilized the Fischer exact, chi-square, or Mann-Whitney U tests to determine the groups differences. The association between the

| Table 1 Baseline characteristics of biliary atresia patients who underwent liver biopsy during Kasai procedure |
|------------------------------|----------------|
| Characteristics | n (%) | Median (IQR) |
| Sex | | |
| • Male | 27 (54) |
| • Female | 23 (46) |
| Age at Kasai procedure performed (days) | 102.5 (75.75–142.25) |
| Type of biliary atresia (BA) | | |
| • 1 | 2 (4) |
| • 2A | 18 (36) |
| • 2B | 6 (12) |
| • 3 | 24 (48) |
| Pre-operative laboratory findings (normal range) | | |
| • Total bilirubin (≤1.0 mg/dL) | 10.76 (7.86–13.6) |
| • Direct bilirubin (0–0.2 mg/dL) | 8.17 (6.45–11.59) |
| • Aspartate aminotransferase (≤540 U/L) | 187 (120.5–242.25) |
| • Alanine aminotransferase (≤541 U/L) | 119 (88.75–168.75) |
| • Gamma glutamyl transferase (7–64 U/L) | 566 (268.5–946.75) |
| • Alkaline phosphatase (≤462 U/L) | 471 (361–648) |
| • Albumin (3.9–4.9 g/dL) | 3.55 (3.23–4.14) |
| • International normalized ratio (0.9–1.1) | 1.025 (0.94–1.205) |
| • Platelet (150–450 × 10³/uL) | 270 (218.75–409.25) |
| Outcomes | | |
| • Survived | 26 (52) |
| • Died | 24 (48) |
| Causes of death | | |
| • Septic shock | 14 (56.5) |
| • Hemorrhagic shock | 4 (17.4) |
| • Multiple organ dysfunction syndrome | 2 (8.7) |
| • Acute respiratory distress syndrome | 4 (17.4) |
histopathological findings and the BA patients’ survival was defined by a log-rank test, while the probabilities of patients’ survival following Kasai operation was plotted using Kaplan-Meier curve.

For analysis of association between histopathological findings and liver cirrhosis/survival of BA patients, we combined “mild” and “moderate” categories into one group, i.e. mild/moderate group for fibrosis, bile duct proliferation, and portal inflammation variables, and pooled “absent”, mild”, and “moderate” categories into one group, i.e. absent/mild/moderate group for cholestasis variable.

Kappa values for bile duct proliferation, fibrosis, cholestasis, giant cell, portal inflammation, and cirrhosis were 0.83, 0.97, 0.75, 0.75, 0.82, and 1.0, respectively.

**Results**

**Clinical characteristics**

The study involved 50 BA patients: 27 males and 23 females. The liver biopsies were conducted at the Kasai procedure, with median age of 102.5 days (interquartile range [IQR], 75.75–142.25) (Table 1). Table 1 provides all pre-operative laboratory findings.

Overall survival of patients with BA was 52%. The causes of the death of BA patients after Kasai are provided in Table 1, while the causes of the death of the non-cirrhotic BA patients (n = 7) were multiple organ dysfunction syndrome (n = 1), septic shock (n = 2), hemorrhagic shock (n = 2), and acute respiratory distress syndrome (n = 2).

**Association of histopathological findings and liver cirrhosis**

First, we analyzed the liver histopathological findings in BA patients and associated them with liver cirrhosis. Among four histopathological findings, bile duct proliferation, cholestasis, and portal inflammation were significantly associated with liver cirrhosis (p = 3.6 × 10^{-6}, 5.6 × 10^{-4}, and 1.6 × 10^{-3}, respectively), whereas giant cell transformation was not (p = 0.77) (Table 2).

Furthermore, the BA patients with severe bile duct proliferation, severe cholestasis, and severe portal inflammation have a higher risk by 27-, 22-, and 19.3-fold, respectively, to develop liver cirrhosis compared with patients with moderate/mild bile duct proliferation, moderate/mild/without cholestasis, and moderate/mild portal inflammation, respectively (Table 2).

**Association among histopathological findings**

Next, we determined whether there is an association among histopathological findings. The bile duct proliferation was strongly correlated with cholestasis and portal inflammation (p = 7.3 × 10^{-5} and 2 × 10^{-4},
respectively), and cholestasis was also significantly associated with portal inflammation ($p = 0.016$) (Table 3).

### Association of histopathological findings with age at Kasai procedure and patients’ survival

Subsequently, we correlated the histopathological findings with the age at Kasai procedure and patients’ survival. The age at Kasai procedure was strongly correlated with the liver cirrhosis ($p = 0.02$), bile duct proliferation ($p = 0.026$), and giant cell transformation ($p = 0.049$) (Table 4), while the degree of fibrosis and cholestasis were significantly correlated with the patients’ survival, with HR of 3.9 (95% CI = 1.7–9.0; $p = 0.017$) and 3.1 (95% CI = 1.4–7.0; $p = 0.016$) (Fig. 2).

Moreover, there was no significant correlation between age at Kasai surgery and patients’ survival ($p = 0.33$; Fig. 3a), with its cutoff value of 72 days (sensitivity 29.2%, specificity 84.6%, and AUC 0.51 [95% CI = 0.36–0.65] (Fig. 3b).

### Table 2: Association of histopathological findings and liver cirrhosis in BA patients after Kasai procedure

| Histopathological findings | Liver cirrhosis (+) | Liver cirrhosis (−) | $p$-value | OR (95% CI) |
|----------------------------|---------------------|---------------------|-----------|-------------|
| Bile duct proliferation    |                     |                     |           |             |
| √ Severe                   | 27                  | 3                   | 3.6 x 10^-6* | 27 (5.6–129.1) |
| √ Moderate/mild            | 5                   | 15                  |           |             |
| Cholestasis                |                     |                     |           |             |
| √ Severe                   | 18                  | 1                   | 5.6 x 10^-4* | 22 (2.6–184.7) |
| √ Moderate/mild/absent     | 14                  | 17                  |           |             |
| Portal inflammation        |                     |                     |           |             |
| √ Severe                   | 17                  | 1                   | 1.6 x 10^-3* | 19.3 (2.3–162.6) |
| √ Moderate/mild            | 15                  | 17                  |           |             |
| Giant cell transformation   |                     |                     |           |             |
| √ Positive                 | 17                  | 11                  | 0.77      | 0.7 (0.2–2.3) |
| √ Negative                 | 15                  | 7                   |           |             |

* $p < 0.05$ is considered statistically significant

### Table 3: Association among histopathological findings of liver biopsy in BA patients after Kasai procedure

| Histopathological findings | Bile duct proliferation | Portal inflammation | Giant cell transformation | Cholestasis |
|----------------------------|-------------------------|---------------------|--------------------------|-------------|
|                            | Severe                  | Moderate/mild/absent|                         |             |
| Cholestasis                |                         |                     |                          |             |
| √ Severe                   | 18                      | 1                   | 7.3 x 10^-5*             | 28.5 (3.4–242.1) |
| √ Moderate/mild/absent     | 12                      | 19                  |                          |             |
| Portal inflammation        |                         |                     |                          |             |
| √ Severe                   | 17                      | 1                   | 2 x 10^-4*               | 24.8 (2.9–210.5) |
| √ Moderate/mild            | 13                      | 19                  |                          |             |
| Giant cell transformation   |                         |                     |                          |             |
| √ Positive                 | 15                      | 13                  | 0.39                     | 0.5 (0.2–1.7) |
| √ Negative                 | 15                      | 7                   |                          |             |

* $p < 0.05$ is considered statistically significant

BA biliary atresia, OR odds ratio, CI confidence interval
Association of pre-operative laboratory findings and liver cirrhosis

None of pre-operative laboratory findings, including total bilirubin ($p = 0.79$), were associated with the development of liver cirrhosis (Table 5).

Discussion

Our study is able to find evidence that bile duct proliferation, cholestasis, and portal inflammation are predictor factors for the liver cirrhosis development in patients with BA following Kasai procedure in Indonesia. These findings repeat those reported in previous studies [6, 8, 10], but, there are two novelities in our report: 1) it was performed in Indonesia (versus Indian [6, 8] and Brazilian [10] population); and 2) we associated the histopathological findings with the liver cirrhosis, age at Kasai procedure, and BA patients’ survival (versus the clearance of jaundice [8] and survival [6, 10]). In contrast, Czubkowski et al. [7] concluded that liver histopathological findings have a limited value as prognostic factors for BA patients.

Bile duct proliferation has been shown as a prognostic factor for BA patients. More severe bile duct proliferation has the worst prognosis [6] and increased degree of fibrosis [10]. Our study provides new evidence from a different population that the bile duct proliferation might predict the liver cirrhosis development in patients with BA after Kasai procedure. Furthermore, our findings also support that cholestasis has a prognostic significance for BA patients as reported by Muthukanagarajan et al. [6].

Several studies showed an inconsistent result regarding the role of portal inflammation for prognosis of BA patients [6, 7, 11]. Our result supports the finding that portal inflammation is a prognostic factor for BA patients [11].

Giant cells were seen in 48% of BA patients which is similar with previous studies that ranged from 20 to 50% [12–14]. It has been hypothesized that giant cells are the best indicator for diagnosis of neonatal hepatitis, but not BA [9, 12–14]. Our study also shows that giant cells do not function as a prognostic factor for liver cirrhosis development. These findings are compatible with previous report [7]. However, Azarow et al. [15] revealed that the presence of giant cells is correlated with the failure of the Kasai procedure. These differences might be associated with the subjectivity of histological assessment [7, 16].

Interestingly, the bile duct proliferation revealed a strong association with both cholestasis and portal inflammation and the cholestasis showed a significant association with portal inflammation. Further study is necessary to investigate how they might influence each other and promote the development of liver cirrhosis.

BA will lead to liver cirrhosis and results in either transplantation or death at a young age if without early diagnosis and Kasai surgery [1, 2]. Thus, the
**Fig. 2** Kaplan-Meier analyses of patients’ survival with BA after Kasai procedure according to the histopathological findings. The degree of fibrosis (a) and cholestasis (d) were significantly correlated with the patients’ survival, with hazard ratio of 3.9 (95% CI = 1.7–9.0; \(p = 0.017\)) and 3.1 (95% CI = 1.4–7.0; \(p = 0.016\)), while bile duct proliferation (b), portal inflammation (c), and giant cell transformation (e) were not (\(p > 0.05\)).
possibility of the liver cirrhosis, especially in BA patients with the severe form of bile duct proliferation, cholestasis, and portal inflammation, even following a Kasai surgery should be clarified during counseling to the families.

It should be noted that we performed the liver biopsy during the Kasai procedure only, therefore, we were unable to find the association between the development of liver cirrhosis and the elapsed time following the surgery, becoming a weakness of our report. Moreover, the degree of fibrosis and cholestasis were associated with the BA patients’ survival in our cohort after Kasai surgery. Some histopathological features, including fibrosis degree, were strongly associated with the risk of transplantation [17]. Unfortunately, due to the very few cases of pediatric liver transplant in our hospital \( (\text{n} = 5) \), we were unable to analyze the association between histopathological findings and transplantation risk.

The association between age at Kasai procedure and prognosis of BA patients is still controversial. Some studies showed that earlier age of Kasai has a good prognosis for BA patients’ survival [18–20], while other reports did not support this association [21–23]. Our study revealed that age at Kasai procedure had a strong correlation with the development of liver cirrhosis, but not on patients’ survival.

Finally, caution should also be taken when generalizing about these results because this was a single-institutional study and used a small sample size. These limitations indicate that a multicenter study with a larger sample of cases is further needed to confirm our study.

**Conclusions**

Histopathological findings of bile duct proliferation, cholestasis, and portal inflammation can predict the liver cirrhosis development in patients with BA. Furthermore, degree of fibrosis and cholestasis affect the patients’ survival after the Kasai procedure.

**Table 5** Association of pre-operative laboratory findings and liver cirrhosis in BA patients

| Laboratory Findings          | Liver Cirrhosis (median, [IQR]) | \( p \)-value |
|------------------------------|----------------------------------|--------------|
| Total bilirubin (mg/dL)      | 11.03 (7.72–13.97)               | 9.88 (8.51–12.55) | 0.79 |
| Direct bilirubin (mg/dL)     | 9.17 (6.85–11.89)                | 7.79 (7.52–8.85) | 0.38 |
| Aspartate aminotransferase (U/L) | 212 (157–249)                  | 133 (110–231)   | 0.07 |
| Alanine aminotransferase (U/L) | 117 (72–164)                   | 121 (68–176)    | 0.94 |
| Gamma glutamyl transferase (U/L) | 568 (323–887)                 | 541 (230.5–1002) | 0.62 |
| Alkaline phosphatase (U/L)   | 456 (347.5–681)                 | 526 (425.5–641.5) | 0.68 |
| Albumin (g/dL)               | 3.46 (3.23–3.71)                | 3.73 (3.36–4.14) | 0.33 |
| International normalized ratio | 1.01 (0.94–1.32)               | 1.03 (0.99–1.14) | 0.69 |
| Platelet \( (x10^3)/\text{μL} \) | 254 (220–391)                  | 321 (213–428)   | 0.73 |

BA biliary atresia, IQR interquartile range
Abbreviations
ALT: alanine aminotransferase; ALP: alkaline phosphatase; AST: aspartate aminotransferase; AUC: area under curve; BA: biliary atresia; CI: confidence interval; GGT: gamma glutamyl transferase; HR: hazard ratio; INR: international normalized ratio; IQR: interquartile range; ROC: receiver operating characteristic.

Acknowledgments
We are thankful to all those who offered excellent technical help during the study, especially Dewi Ismamaitoh (Clinical Epidemiology and Biostatistics Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital) for her statistics help. Some results for the manuscript are from Dian Nirmala Sari’s and Leila Rachma Budiantri’s thesis.

Authors’ contributions
G conceived the study and drafted the manuscript, and NY, HTR and AM critically revised the manuscript for important intellectual content. G, DNS, LRB, VMWP, ARF, FR, DA, N’ and HTR analyzed and collected the data, and G, NY, HTR, and AM facilitated all project-related tasks. All authors read and approved the final manuscript.

Funding
The work was supported by a grant from the Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada (AM and G).

Availability of data and materials
All data generated or analyzed during this study are included in the submission. The raw data are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the Ethics Committee of Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital (KE/FK/0506/EC/2020) and KE/FK/528/EC/2015 and KE/FK/0506/EC/2020).

Consent for publication
Not applicable.

Competing interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Authors’ contributions
G conceived the study and drafted the manuscript, and NY, HTR and AM critically revised the manuscript for important intellectual content. G, DNS, LRB, VMWP, ARF, FR, DA, N’ and HTR analyzed and collected the data, and G, NY, HTR, and AM facilitated all project-related tasks. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the Ethical Committee of Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital (KE/FK/0506/EC/2020).

Consent for publication
Not applicable.

Competing interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Author details
1Pediatric Surgery Division, Department of Surgery, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Jl. Kesehatan No. 1, Yogyakarta 55281, Indonesia. 2Department of Anatomical Pathology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Jl. Kesehatan No. 1, Yogyakarta 55281, Indonesia.

Received: 22 April 2020 Accepted: 25 June 2020
Published online: 02 July 2020

References
1. Lakshminarayanan B, Davenport M. Biliary atresia: a comprehensive review. J Autoimmun. 2016;73:1–9.
2. Ağın M, Tümgör G, Alkan M, et al. Clues to the diagnosis of biliary atresia in neonatal cholestasis. Turk J Gastroenterol. 2016;27:37–41.
3. Gunadi, Gunawan TA, Widiyanto G, Yuanita A, Mulyani NS, Makhmudi A. Liver transplant score for prediction of biliary atresia patients’ survival following Kasai procedure. BMC Res Notes. 2018;11:581.
4. Chiu CY, Chen PH, Chan CF, et al. Biliary atresia in preterm infants in Taiwan: a nationwide survey. J Pediatr. 2013;163:100–3.
5. Livsey E, Cortina Borja M, Shafir K, et al. Epidemiology of biliary atresia in England and Wales (1999-2006). Arch Dis Child Fetal Neonatal Ed. 2009;94:F451–5.
6. Musthukanganagan SJ, Kamar I, Srinivasan P, et al. Diagnostic and prognostic significance of various histopathological features in extrahepatic biliary atresia. J Clin Diagn Res. 2016;10:EC23–7.
7. Czubkowskł P, Cielecka-Kuszyk J, Ruraz M, et al. The limited prognostic value of liver histology in children with biliary atresia. Ann Hepatol. 2015;14:902–9.
8. Gupta I, Gupta SD, Bhatnagar V. Extrahepatic biliary atresia: correlation of histopathology and liver function tests with surgical outcomes. J Indian Assoc Pediatr Surg. 2012;17:147–52.
9. Rashed YK, Saber MA, Tawfik M, Mourad WS. Histopathological features and accuracy for diagnosis biliary atresia by prelaparotomy liver biopsy in Egypt. Egypt Pediatr Assoc Gaz. 2013;61:42–5.
10. Santos JL, Kelling CO, Meurer L, et al. The extent of biliary proliferation in liver biopsies from patients with biliary atresia at portoenterostomy is associated with the postoperative prognosis. J Pediatr Surg. 2009;44:695–701.
11. Kahn E. Biliary atresia revisited. Pediatr Dev Pathol. 2004;7:109–24.
12. Morotti RA, Jain O. Pediatric cholestatic disorders. Approach to pathologic diagnosis. Surg Pathol. 2013;36:205–25.
13. Davenport M, Tizzard SA, Underhill J, et al. The biliary atresia splenic malformation syndrome: a 28-year single-center retrospective study. J Pediatr. 2006;149:393–400.
14. Rastogi A, Krishnan N, Yachha SK, et al. Histopathological features and accuracy for diagnosing biliary atresia by prelaparotomy liver biopsy in developing countries. J Gastroenterol Hepatol. 2009;24:97–102.
15. Azarov KS, Phillips MJ, Sandler AD, et al. Biliary atresia: should all patients undergo a portoenterostomy? J Pediatr Surg. 1997;32:168–72.
16. Yeh MMA. Pathologic diagnosis of biliary atresia on liver biopsy: is tissue the issue? J Gastroenterol Hepatol. 2009;24:933–40.
17. Russo P, Magee JC, Anders RA, Bove KE, Chung C, Cummings OW, et al. Key histopathologic features of liver biopsies that distinguish biliary atresia from other causes of infantile cholestasis and their correlation with outcome: a multicenter study. Am J Surg Pathol. 2016;40:1601–15.
18. Shneider BL, Magee JC, Karpen SJ, Rand EB, Narkewicz MR, Basi LM, et al. Total serum bilirubin within 3 months of hepatopportoenterostomy predicts short-term outcomes in biliary atresia. J Pediatr. 2016;170:211–7.
19. Serinet MO, Wildhaber BE, Broué P, Lachaux A, Sarles J, Jacquemin E, et al. Impact of age at Kasai operation on its results in late childhood and adolescence: a rational basis for biliary atresia screening. Pediatrics. 2009;123:1280–6.
20. Nio M, Ohi R, Miyano T, Saeki M, Shiraki K, Tanaka K, et al. Five- and 10-year survival rates after surgery for biliary atresia: a report from the Japanese biliary atresia registry. J Pediatr Surg. 2003;38:997–1000.
21. Wong KK, Chung PH, Chan IH, Lam LC, Tam PK. Performing Kasai portoenterostomy beyond 60 days of life is not necessarily associated with a worse outcome. J Pediatr Gastroenterol Nutr. 2010;51:631–4.
22. Schoen BT, Lee H, Sullivan K, Ricketts RR. The Kasai portoenterostomy: when is it too late? J Pediatr Surg. 2001;36:97–9.
23. Ramos-Gonzalez G, Elsiofon S, Dee EC, Staffa SJ, Medford S, Lillehei C, et al. Predictors of need for liver transplantation in children undergoing hepatopportoenterostomy for biliary atresia. J Pediatr Surg. 2019;54:1127–31.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions